Immune Monitoring in Infectious Diseases

Monitor Cellular Immunity to Common Viral Infections

Define factors of protective immunity and identify effective vaccine antigens

 

Central to human antiviral immunity is the activation of virus-specific T cells. Detection of cellular immunity can provide an insight into the patient’s general immune status before, during, and after immunotherapy. Furthermore, tracking virus-specific T cells presence reveals immune status and can anticipate the risk of severe disease progression in immunocompromised patients.

Predefined products and Panels of Dextramer® reagents address highly relevant viral infections. Alternatively, select antigens of interest from our menu – or define custom Dextramer® reagents.

Virus Dextramer® Panel

Measure immune status with selected Dextramer® reagents displaying epitopes of the opportunistic cytomegalovirus, Epstein-Barr virus, influenza, and BK virus.
Opportunistic viruses can cause severe diseases in immune-compromised patients. Measuring the virus immune status is an important tool to check the risk of infection in immune-compromised patients.

Order MHC Dextramer® Virus Panel

The MHC Dextramer® Virus Panel consists of Dextramer® reagents, displaying immunodominant, well-characterized epitopes derived from four general and opportunistic viruses: Cytomegalovirus (CMV), Epstein-Barr virus (EBV), Influenza, and BK virus and a negative control Dextramer®.

Cat. No. RX03 - Virus-specific Dextramer®

MHC Allele

Peptide

Virus Tests* 
HLA-A*0201 NLVPMVATV CMV 50 tests
HLA-A*0201 GLCTLVAML EBV 50 tests
HLA-A*0201 GILGFVFTL Influenza 50 tests
HLA-A*0201 LLMWEAVTV BK virus 50 tests
HLA-A*0201 Negative Control  - 50 tests

* One test is defined as 10 µl MHC Dextramer® reagent sufficient to stain up to 1-3 x 10^6 lymphoid cells or 1-3 x 10^5 clonal antigen-specific T cells.

Virus Dextramer® Panel is for research use only.

Immudex has updated the catalog numbers. To learn more about it, please consult the document here

COVID-19 Dextramer® Panels

A deeper understanding of COVID-19 immunity is needed to explore vaccine responses, long-term immunity, predict patients at risk, and even prepare ourselves for a possible new pandemic in the future.
Our unique immune monitoring tools can help you unravel the SARS-CoV-2 specific T-cell immunity in an easy and reproducible way.

Order COVID-19 Specific Dextramer® Products

Unravel T-cell response to SARS-CoV-2 infection with a dedicated set of Dextramer® products featuring T-cell epitopes validated in COVID-19 patients.

We provide four SARS-CoV-2 Panels, each with a curated collection of SARS-CoV-2-specific Dextramer® reagents displaying validated T-cell epitopes. Select the one most suitable for your research:

  • SARS-CoV-2 Spike Panel
  • SARS-CoV-2 A*0201 Panel
  • SARS-CoV-2 Multi Allele Panel
  • SARS-CoV-2 Custom Panel

For more details, please read here or contact us

CMV Dextramer® Panel

CMV infection and disease pose a major risk in immunosuppressed patients. Reactivation of CMV is a frequently occurring complication and can contribute to morbidity and mortality if not controlled. CMV-specific CD8+ T cells are considered the main factor in successful management of CMV infection. In transplant patients, a low number of CMV-specific CD8+ T cells are predictive for development of CMV-related complications.​

Support successful management of cytomegalovirus infection in transplant patients with well-characterized, virus-specific epitopes.

Order MHC Dextramer® CMV Panel

The MHC Dextramer® CMV Panel consists of Dextramer® reagents, displaying immunodominant, well-characterized epitopes derived from CMV-specific antigens and a negative control Dextramer®.

Cat. No. RX04 - CMV-specific Dextramer®

MHC Allele
Peptide Antigen Tests*
HLA-A*0101 VTEHDTLLY pp50 50 tests
HLA-A*0201 NLVPMVATV pp65 2 x 50 tests
HLA-A*0301 KLGGALQAK IE-1 50 tests
HLA-A*2402 QYDPVAALF pp65 50 tests
HLA-B*0702 RPHERNGFTVL pp65 50 tests
HLA-B*0702 TPRVTGGGAM pp65 50 tests
HLA-B*0801 ELRRKMMYM pp65 50 tests
HLA-B*3501 IPSINVHHY pp65 50 tests
General Negative Control  -  3 x 50 tests

* One test is defined as 10 µl MHC Dextramer® reagent sufficient to stain up to 1-3 x 10^6 lymphoid cells or 1-3 x 10^5 clonal antigen-specific T cells.

MHC Dextramer® CMV Panel is for research use only. For In Vitro Diagnostics (IVD) use please visit the Dextramer® CMV Kit product page.

Immudex has updated the catalog numbers. To learn more about it, please consult the document here

EBV Dextramer® Panel

EBV is a persistent virus that infects 90% of the human population. Primary infection may cause acute infectious mononucleosis, and persistent infection may be associated with the development of several malignancies. T cells play a critical role in controlling both the primary and persistent phases of infection.

Detect, quantify, and isolate EBV-specific T cells and obtain information about the patients’ virus immune status.

Order MHC Dextramer® EBV Panel

The panel consists of Dextramer® reagents displaying immunodominant, well-characterized epitopes derived from EBV-associated antigens and a negative control Dextramer.

Cat. No. RX05 - EBV-specific Dextramer®

MHC Allele

Peptide

Antigen Tests*
HLA-A*0201 GLCTLVAML BMLF-1 50 tests
HLA-B*3501  HPVGEADYFEY EBNA-1 50 tests
HLA-B*0702  RPPIFIRRL EBNA-3A 50 tests
HLA-B*0801  FLRGRAYGL EBNA-3A 50 tests
General Negative Control  - 50 tests

* One test is defined as 10 µl MHC Dextramer® reagent sufficient to stain up to 1-3 x 10^6 lymphoid cells or 1-3 x 10^5 clonal antigen-specific T cells.

The MHC Dextramer® EBV Panel is for research use only.

Immudex has updated the catalog numbers. To learn more about it, please consult the document here

See how dCODE Dextramer® technologies can advance all vaccine development phases,
from selecting candidate viral epitopes to monitoring vaccine efficacy by measuring antigen-specific immunity.